Several mTOR inhibitors, such as rapamycin and its analogs (rapalogs), are being investigated for their therapeutic potential. These inhibitors can block the mTOR pathway, thus hindering cancer cell growth and inducing apoptosis. Clinical trials are ongoing to assess the efficacy and safety of these drugs in treating gynecological malignancies.
